Larry Gerrans, the founder and CEO of Sanovas, a life sciences holding company based in San Rafael, California, that is focused on developing technology to treat the deadliest cancer of them all: Lung Cancer joins eHealth Radio and the Cancer Prevention and Health News Channels.
On this episode, Sanovas CEO Larry Gerrans warns that existing resources to treat peripheral tumors are “grossly inadequate” as Medicare coverage of lung cancer screening for at-risk beneficiaries is now in effect.
Listen to interview with host Eric Michaels and guest Larry Gerrans discuss the following:
- Please explain what this means?
- Why is this controversial?
- What can be done about the shortage of therapeutic resources to treat lung cancer?
- What is your company doing to provide a solution to the shortage of therapeutic resources to treat lung cancer?
- What can our listeners do to help?
An innovator and visionary, Larry Gerrans is a passionate leader whose inventions and pursuits, on behalf of the Life Sciences, have created meaningful and enduring contributions to humanity. For more than 20 years, Mr. Gerrans has played a leading role in the innovation and deployment of minimally invasive surgical (MIS) techniques, devices and implant systems for the burgeoning endoscopic markets in the Cardio-Thoracic, General Surgery, Urological, Neuro-surgical, Gynecological, ENT, Orthopedic, Spine and Sports Medicine arenas. Many of his pioneering contributions have become the ‘Gold Standard’ for diagnostic and therapeutic intervention across these Life Sciences.
His cutting edge research and development teams, comprised of Scientists, Doctors, Engineers and business development teams, many of whom were among the first medical industry personnel to enter the National Laboratories to evaluate various state of the art technologies for transfer to private industry, have created lifesaving technologies that now serve to remedy millions of people worldwide who suffer from acute injury, severe illness and chronic disease. These innovations now positively affect the lives of over 100 million people and relate to more than $15 Billion in revenues, annually.
Mr. Gerrans leveraged his contributions in endoscopic imaging and communications technologies to incept telemedicine broadcasting and electronic surgical records. He conceived and led the commercialization efforts of the first voice-activation technology for surgical device control in the operating theatre – the Hermes™ voice activation system. He conducted the human factor analysis and IT integration that created the most technologically advanced operating rooms ever created, the Endoscopic Surgical Suite (Endo-Suite™) and the Digital Operating Room (Digital OR™). These contributions are credited with leading to what is now a multibillion dollar healthcare facilities construction and IT marketplace.
As the Founder, President & CEO of Sanovas, Inc., Mr. Gerrans has written over 100 patents and has been leading an elite group of innovators developing ground breaking interventional technologies to treat the diseases of the Lung and to cure Lung Cancer. The Sanovas platform features highly sophisticated 3D imaging and physiologic intelligence systems that operate within new sensory guided interventional technologies to provide the local delivery of drug and immune therapies to significantly improve cancer treatment.
A byproduct of Gerrans’ teams success in advancing miniaturization, to overcome the procedural risks and technological challenges of the pulmonary anatomy, has been the development of entirely new classes of Interventional Catheters, Surgical Camera’s, Physiologic Measurement and Bio-Feedback Systems, In Vivo Diagnostics and In Vivo Drug Delivery Systems. These ‘Core’ technologies have given rise to more than 10 subsidiary companies. One, of which, promises to develop the next generation of surgical robots.
Mr. Gerrans is also the Founder and Chairman of Human Tissue Banks International, Inc., a 501(c)3 nonprofit corporation that is providing allograft resources to the highly promising innovations being forged in bio-regenerative medicine, 3-D printing of organs, “Bio-Inks” and Stem Cell Engineering.